Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (270)	6/9/2004 9:11:35 AM
From: Icebrg	Read Replies (2) \| Respond to of 362

>>Erik, do you remain skeptical of TTP>> Yes, I am. I have sold most of the shares I held, but have kept some. Generally speaking, I think things do look somewhat "better" now than what they did a year or so ago. In the short term what happens to Pivanex will be very important to the company. I was very doubtful about that product, but with all the publicity surrounding HDAC inhibitors and Velcade they might have something worth developing and which could be of interest to Millennium. They are, as you might know, running a fairly large NSCLC phase IIb, which is expected to be reported upon towards the end of the year. If those results in any way are positive there will be a revaluation of the company. If not - then not. As for Iloperidone, I believe the drug may be resurrected, but it will most probably never become more than a niche drug and the returns for Titan will be correspondingly low. The backgrounds of the people behind Vanda is interesting. Evidently they should have a good idea about what they are doing. And with Singapore in the background, I suppose that funding should not be a problem. Erik